BridgeBio
BBIO
Performance
About BridgeBio
BridgeBio is a biopharmaceutical company focused on designing transformative medicines for patients with genetic diseases and cancers driven by clear genetic drivers. It develops and advances therapies across its pipeline, including products like Attruby (acoramidis) and Nulibry (fosdenopterin), aiming to bring clinically meaningful cures to patients. The company emphasizes a platform that accelerates discovery and development, combining science and finance to support patients and partners. Headquartered in Palo Alto, California, BridgeBio engages in research, collaborations, and patient-focused initiatives to address rare genetic diseases and oncology indications.
Recent News
Rare Disease Vouchers Caught in Political Abyss. It Didn’t Have To Be This Way
Yuviwel Gets FDA Greenlight as First Once‑Weekly Treatment for Dwarfism in Children
Alfasigma Gains Neuro Treatment; BridgeBio Offers $550M in Notes
Despite Wide Support for Rare Disease, Voucher Program Caught Up in Senate's ICE Fight
Recent Deals
No recent deals for this company.
